2024 A Focus on Surgical Oncology

ACI: A Focus on Surgical Oncology

Saturday, march 23, 2024 
12:30-2:30 p.m. ET
live at sso 2024 in Atlanta, ga

Join SITC and a panel of experts for an afternoon of in-depth education on all aspects of the clinical implementation of surgical immunotherapy.

SITC is pleased to present this session in collaboration with the Society of Surgical Oncology as part of SSO’s 2024 Annual Meeting. 

Presentations will address immunotherapy in the adjuvant and neoadjuvant settings, care in the neoadjuvant and adjuvant setting, and T cell therapies and the role of the surgeon.

The 2024 Advances in Cancer Immunotherapy™ series is supported, in part, through independent medical education grants from AstraZeneca, Bristol Myers Squibb, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc.  (MSD), and Novartis Pharmaceuticals Corporation (supporters as of March 22, 2024).

Session Organizers

Genevieve M. Boland, MD, PhD
Massachusetts General Hospital

Simon Turcotte, MD, MSc, FRCSC
Université de Montréal

Program Snapshot

Credits Available
Physician Education: 2 AMA PRA Category 1TM

Program Date & Location

Saturday, March 23, 2024 at 12:30-2:30 p.m. ET
Live at SSO 2024 in Atlanta, GA

Program Cost

Free with registration to SSO.

Register for A Focus on Surgical Oncology >

Session Agenda

12:30 p.m.



12:40 p.m.


Neoadjuvant Immune Checkpoint Inhibitors for Resectable Cancer at High Risk of Recurrence
Stephanie Downs-Canner, MD – Memorial Sloan Kettering Cancer Center

1:05 p.m.

  Personalized Vaccines in the Adjuvant Setting
Mark B. Faries, MD – The Angeles Clinic and Research Institute

1:30 p.m.


T Cell Therapies for Metastatic Solid Cancer
Simon Turcotte, MD – Université de Montréal

1:55 p.m.


Clinical Case Discussions: Case Studies on Neoadjuvant Immunotherapy
Moderator: Genevieve Boland, MD, MSc, FRCSC – Massachusetts General Hospital

2:25 p.m.


Closing Remarks


This program is part of the SITC ACI series. View below to explore more programs in the 2024 ACI series.

Session Details

Session highlights

  • Overview of perioperative immunotherapies and the surgeon’s role in adoptive cellular therapies.

  • Timely updates on the latest clinical advances in the field, including data from recent scientific meetings and clinical trials.

  • Dedicated opportunities for clinicians to ask questions and receive direction on difficult cases.

  • Practical education in caring for patients receiving immunotherapy in combination with surgery.

Target Audience

The Advances in Cancer Immunotherapy™ (ACI) programs aim to reach practicing clinical oncologists, nurses, nurse practitioners, advanced practitioners, pharmacists, emergency physicians, and other allied health professionals who wish to learn the basic principles of cancer immunotherapy and the most up-to-date clinical data for these treatments, in a multitude of disease states/therapeutic areas, in order to inform and integrate into their own clinical practice. In-training oncologists and hospital administrators will also find the program beneficial.

Venue Information

Georgia World Congress Center- Building C
285 Andrew Young International Blvd NW Atlanta, GA 30313 

Steps from the convention center’s doors, visitors will find 22-acre Centennial Olympic Park, state-of-the-art Mercedes-Benz Stadium, home to the Atlanta Falcons and Atlanta United, Chick-fil-A College Football Hall of Fame, and the Atlanta Hawks’ recently renovated nest, State Farm Arena.

Accreditation Information 

American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC)


Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 2 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Physician Continuing Medical Education

PACE designates this live activity for a maximum of 2 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Joint Accreditation Statement

thumbnail image In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and the Society for Immunotherapy of Cancer (SITC). PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


Disclosure of Conflicts of Interest

PACE requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant financial relationships are mitigated according to PACE policies.